Беспонза
(инотузумаб озогамицин)
(1 mg)
(one)
(Леофілізат)
Besponsa (Inotuzumab ozogamicin ) 0.9 mg Pfizer
In Stock
Indications
Inotuzumab ozogamicin is indicated as monotherapy for the treatment of adult patients with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL), including adult patients with Philadelphia chromosome-positive (Ph+) B-cell precursor ALL after failure of therapy with at least one tyrosine kinase inhibitor (TKI).
-
Commercial name:Беспонза
-
Сhemical name:инотузумаб озогамицин
-
Dosage:1 mg
-
Quantity:one
-
Release form:Леофілізат
-
Виробник:Pfizer
No reviews yet